Chemotherapy for stage III-A Hodgkin’s disease: The proper role
Despite the availability of results from a large number of clinical trials, therapy of stage III-A Hodgkin’s disease remains a subject of controversy as chemotherapy alone, radiotherapy alone, and combined modality therapy have all been advocated as optimal treatment for patients with stage III-A Hodgkin’s disease. In this paper I will review the data which supports each of these therapeutic recommendations. However, the majority of this paper will review the evidence that there is no one optimal therapy for stage III-A Hodgkin’s disease, and that, instead, anatomic substage — the extent of nodal disease within the abdomen — should be the critical factor in allocating stage III-A Hodgkin’s disease patients to different therapies.
KeywordsCombine Modality Therapy Hepatic Involvement Visceral Dissemination Radiotherapy Port Splenic Involvement
Unable to display preview. Download preview PDF.
- 1.DeVita VT, Simon RM, Hubbard SM, et al.: Curability of advanced Hodgkin’s disease with chemotherapy. Ann Intern Med 92: 587–595, 1980.Google Scholar
- 14.DeVita VT, Simon RM, Hubbard SM, et al.: Curability of Advanced Hodgkin’s disease with chemotherapy. Ann of Intern Med 92: 587–595, 1980.Google Scholar
- 24.Lowenbraum S, Ramsey H, Sutherland J, et al.: Diagnostic laparotomy and splenectomy for staging Hodgkin’s disease. Ann Intern Med 72: 655, 1970.Google Scholar
- 27.Prosnitz LR, Montalvo RL, Fischer DB, et al.: Treatment of stage IIA Hodgkin’s disease: Is radiotherapy alone adequate? Int J Radiat Oncol Biol Phys 4: 481–787, 1978.Google Scholar